Pfizer's trispecific antibody shows positive results in atopic dermatitis

March 9, 2026 6:45 AM

Pfizer Inc. (NYSE: PFE) announced that its Phase 2 study of tilrekimig met its primary endpoint in adults with moderate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found